Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 21/7/2018
SIETES contiene 92427 citas

 
 
 1 a 20 de 110 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Tsujimoto T, Kajio H, Shapiro MF, Sugiyama T. Risk of all-cause mortality in diabetic patients taking ß-blockers. Mayo Clin Proc 2017;93:409-18. [Ref.ID 102505]
2. Cita con resumen
Ham AC, van Dijk SC, Swart KMA, Enneman AW, van der Zwaluw NL, Brouwer-Brolsma EM, van Schoor NM, Zillikens MC, Lips P, de Groot LCPGM, Hofman A, Witkamp RF, Uitterlinden AG, Stricker BH, van der Velde N. Beta-blocker use and fall risk in older individuals: Original results from two studies with meta-analysis. Br J Clin Pharmacol 2017;83:2292-302. [Ref.ID 102082]
3. Cita con resumen
Anónimo. Beta blockers and the risk of CV events in type 2 diabetes. Diabetes in Control 2017:29 de julio. [Ref.ID 101936]
4.Tiene citas relacionadas
Sternlicht H, Bakris GL. Spironolactone for resistant hypertension—hard to resist?. Lancet 2015;386:2032-4. [Ref.ID 99769]
5.Tiene citas relacionadas Cita con resumen
Williams B, MacDonald TM, Morant S, Webb DJ, Sever P, McInnes G, Ford I, Cruickshank JK, Caulfield MJ, Salsbury J, Mackenzie I, Padmanabhan S, Brown MJ, for The British Hypertension Society's PATHWAY Studies Group. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet 2015;386:2059-68. [Ref.ID 99524]
6.
Bolsin S, Colson M, Marsiglio A. Perioperative beta blockade for non-cardiac surgery. BMJ 2013;347:9. [Ref.ID 96266]
7. Cita con resumen
Díez-Manglano J. Análisis económico del tratamiento de la insuficiencia cardiaca con betabloqueantes. Med Clin (Barc) 2013;141:265-70. [Ref.ID 96079]
8. Cita con resumen
Morden NE, Schwartz LM, Fisher ES, Woloshin S. Accountable prescribing. N Engl J Med 2013;369:299-302. [Ref.ID 95875]
9. Cita con resumen
Anónimo. Beta-adrenergic blockers and breast cancer. Med Lett Drugs Ther 2012;54:6-7. [Ref.ID 92268]
10.
Waller DG, Waller JR. ß blockers for heart failure with reduced ejection fraction. BMJ 2011;343:691. [Ref.ID 91733]
11.
Krum H, Teerlink JR. Heart failure 2. Medical therapy for chronic heart failure. Lancet 2011;378:713-21. [Ref.ID 91440]
12.Enlace a cita originalTiene citas relacionadas Cita con resumen
Short PM, Lipworth SIW, Elder DHJ, Schembri S, Lipworth BJ. Effect of a beta blockers in treatment of chronic obstructive pulmonary disease: a retrospective cohort study. BMJ 2011;342:1068. [Ref.ID 90941]
13.Tiene citas relacionadas Cita con resumen
Kazani S, Israel E. Treatment with beta blockers in people with COPD. BMJ 2011;342:d2655. [Ref.ID 90940]
14. Cita con resumen
Goldberger JJ, Bonow RO, Cuffe M, Dyer A, Rosenberg Y, O'Rourke R, Shah PK, Smith Jr SC, for the PACE-MI Investigators. ß-blocker use following myocardial infarction: low prevalence of evidence-based dosing. Am Heart J 2010;160:435-43. [Ref.ID 89225]
15.
Arroll B, Doughty R, Andersen V. Investigation and management of congestive heart failure. BMJ 2010;341:190-5. [Ref.ID 88929]
16. Cita con resumen
Chopra V, Eagle KA. Perioperative beta-blockers for cardiac risk reduction. Time for clarity. JAMA 2010;303:551-2. [Ref.ID 87824]
17. Cita con resumen
Solà R, Boj M, Hernández-Flix S, Camprubí M. Silica in oral drugs as a possible sarcoidosis-inducing antigen. Lancet 2009;373:1943. [Ref.ID 87466]
18. Cita con resumen
Krum H. Consider beta blockers for patients with heart failure. BMJ 2009;338:1384-5. [Ref.ID 86003]
19. Cita con resumen
Krum H, Abraham WT. Heart failure. Lancet 2009;373:941-55. [Ref.ID 85474]
20. Cita con resumen
Varcoe S. Merck KGaA joins GSK in issuing no guidance. Scrip 2009;3434:11. [Ref.ID 85404]
Seleccionar todas
 
 1 a 20 de 110 siguiente >>